Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Micro Exam 2 > Ebright: Viral Hepatitis > Flashcards

Ebright: Viral Hepatitis Flashcards

1
Q

Viral Hepatitis Definition:

A

Inflammation and damage to the liver (can be caused by infectious and non-infectious agents)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Viral Hepatitis

Most Common Agents: (3)

A

HAV
HBV
HCV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Viral Hepatitis

Less Common Agents: (6)

A 
HDV
HEV
Epstein-Barr
CMV
HSV
Yellow Fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Is Bacteria Hepatitis common?

A

Less common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bacteria Hepatitis

Less Common Agents: (5)

A 
Leptospirosis
Syphilis
Q fever (Ricketssia)
Tuberculosis
Brucellosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fungal Hepatitis

Less Common Agents: (2)

A

Histoplasmosis*
Candidiasis*
(*especially in immunocompromised)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Parasitic Hepatitis

Less Common Agents: (2)

A

Schistosomiasis

Liver flukes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hepatitis
Non-Infectious Causes
Most Common: (4)

A

Drugs/mediations

Alcohol

Cholecystitis (primary problem outside liver, but can be confused with hepatitis)

Obstructed bile duct (primary problem outside liver, but can be confused with hepatitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hepatitis
Non-Infectious Causes
Less Common: (4)

A

Toxins

Anoxia (Lack of O2)

Autoimmune

Wilson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Acute Hepatitis

Liver Changes:

A

Inflammation, ballooning degeneration, apoptosis, macrophage aggregates, fatty change
- pg: 620

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Chronic Hepatitis
Liver Changes:
What distinguishes this from acute hepatitis?

A

Bridging necrosis and bridging fibrosis (signs of cirrhosis or scarring of the liver) are the major distinguishers from acute disease; also fatty change, apoptosis, macrophage aggregates and other symptoms similar to acute
- pg: 620

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CLINICAL PRESENTATION OF VIRAL HEPATITIS:

Range: asymptomatic to fulminant (life-threatening)

Four Clinical Stages:

A

Range: asymptomatic to fulminant (life-threatening)

Four Clinical Stages:
Incubation
Preicteric
Icteric
Convalescence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Viral Hepatitis Presentation

Incubation:

A

Clinically silent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Viral Hepatitis Presentation
Preicteric

When?
Most common initial symptoms:

A

Preicteric: early, prior to appearance of jaundice

Most common initial symptoms: malaise, weakness, anorexia, N/V, vague-dull RUQ pain, low grade fever (not always), hepatomegaly, splenomegaly (~25% of the time)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Viral Hepatitis Presentation
Preicteric

Other variations can occur:
Serum-Sickness Like Syndrome may occur especially with:
Symptoms of Serum-Sickness Like Syndrome: (3)

A

Other variations can occur: headache, myalgia, sore throat, cough

Serum-Sickness Like Syndrome: may also occur before jaundice, especially with HBV

Symptoms: arthralgias/arthritis, urticaria (hives) and fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Viral Hepatitis Presentation
Icetric

Definition:
Symptoms: (3)
What may develop due to severe jaundice?

A

Icetric: presence of jaundice (50-80% do not become jaundiced)

Symptoms: jaundice, dark urine and light stools

Severe Jaundice: pruritis may develop (generalized itching)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Viral Hepatitis Presentation

Convalescence

A

Convalescence: recovery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Fulminant Viral Hepatitis

How common?
Characteristics: (5)
Mortality rate:

A

Fulminant Viral Hepatitis: uncommon

Characteristics: lethargy, somnolence, stupor, asterixis (flapping tremor) or coma; widespread necrosis of liver

High mortality rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acute Viral Hepatitis Presentation
Lab findings

What is dramatically elevated?
How are Alkaline phosphatase, 5’ nucleotidase, gamma-glutamytransferase levels affected? In a patient with cholestasis?
How is bilirubin affected?

A

Dramatically elevated AST and ALT: 8-100 times normal

Other Findings:

Alkaline phosphatase, 5’ nucleotidase, gamma-glutamytransferase all modestly elevated (except when patients present with cholestasis)

Bilirubin is elevated (icteric disease; usually equally direct and indirect forms)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

In acute hepatic disease, what happens to:

Prothrombin time?
Albumin?
Globulin?
Hb?
WBC counts?
A

Remain normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Pathologic findings in acute viral hepatitis

What happens to the hepatic sinusoidal cords?
What does eosinophilic generation result in?
What type of necrosis?

A

Lobular Disarray: disorderly pattern of hepatic sinusoidal cords

Ballooning and eosinophilic degeneration of hepatocytes: eosinophilic generation resulting in free hyaline bodies or Councilman bodies

Spotty necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Pathologic findings in acute viral hepatitis

Where is lymphocyte infiltration?
What are pathologic changes in viral hepatitis probably more likely due to?
Cholestasis:

A

Lymphocyte infiltration: primarily in portal tracts
o Pathologic changes in viral hepatitis probably more likely due to cell mediated immunity that viral cytopathic effects (esp. HBV)

Cholestasis: variable degree; any condition in which bile flow is blocked from the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Chronic Hepatitis develops in what percent of adult patients with the hepatitis B virus?
Newborns?

A

Develops in ~10% of adult patients and ~90% of newborns infected with the virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Inactive Carrier carries what for greater than 6 months?

LFTs:

A

Inactive Carrier: chronic carrier of HBsAg (but HBsAb negative) for greater than 6 months with normal LFTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Chronic Hepatitis:

Carries what for greater than 6 months?
LFTs:
Indicates either:

A

Chronic carrier of HBsAg (but HBsAb negative) for greater than 6 months with abnormal LFTs and abnormal liver biopsy

Indicates either:

  • Immune tolerate hepatitis: mild
  • Immune active hepatitis: moderate to severe
26
Q

In Chronic HBV, what is the patient positive for? (3)
What about acute HBV?
What can this result in?

A

Patient also often positive for “e” Ab (elaborated b virus when it is actively replicating), HBV DNA and DNA polymerase

Note: the patient would also be positive for these during active acute HBV, however, these are not tested for in this type of scenario

Can result in cirrhosis (25-30% of the time) and hepatocellular carcinoma (less common)

27
Q

What happens to 85% of people infected with chronic HCV?

What happens to the other 15%?

A

85% of people infected go on to develop chronic disease (15% spontaneously cured)

28
Q

Chronic HCV

Characteristics: (3)

A

Fluctuating AST/ALTs

Varying degrees of chronic hepatitis

Patients often do not feel sick until very late in its course (advanced disease)

29
Q

Chronic HCV

Can result in:

A

Can result in cirrhosis and hepatocellular carcinoma as well.

30
Q

If a patient has HBV or HCV, it is important to check for Abs to what?

A

If a patient has HBV or HCV, it is important to check for Abs to HAV.

31
Q

Co-infection with HAV increases risk for developing what?

What if there are no Abs to HAV?

A

Co-infection with HAV increases risk for developing fulminant hepatitis

If no Abs to HAV, give vaccine

32
Q

HAV

Virus Particle:
Genome:
Family:

A

Virus Particle: Non-enveloped
Genome: RNA
Family: Picornaviridae

33
Q

HBV

Virus Particle:
Genome:
Family:

A

Virus Particle: Enveloped
Genome: DNA (replicates by reverse transcriptase)
Family: Hepadnaviridae

34
Q

HCV

Virus Particle:
Genome:
Family:

A

Virus Particle: Enveloped
Genome: RNA
Family: Flaviviridae

35
Q

HDV

Virus Particle:
Genome:

A

Virus Particle: Defective virus that uses HBsAg for its envelope
Genome: RNA

36
Q

HEV

Virus Particle:
Genome:

A

Virus Particle: Non-enveloped

Genome: RNA

37
Q

HAV

Incubation Period:
Transmission:
Age Preference:
Pattern of Onset:

A

Incubation Period: ~30 days
Transmission: Fecal-oral
Age Preference: Children and adolescents
Pattern of Onset: Acute

38
Q

HBV

Incubation Period:
Transmission: (4)
Age Preference: Percutaneous vs endemic areas
Pattern of Onset:

A

Incubation Period: ~60-90 days

Transmission:
Percutaneous
Sexual
Vertical
Unspecified (saliva)

Age Preference:
All ages (percutaneous)
Neonates (endemic areas)

Pattern of Onset: Acute or insidious

39
Q

HCV

Incubation Period:
Transmission: (4)
Age Preference:
Pattern of Onset:

A

Incubation Period: ~50 days

Transmission:
Percutaneous 
Sexual 
Vertical (predominantly with HIV coinfection)
Unspecified

Age Preference: All ages

Pattern of Onset: Insidious

40
Q

HDV

Incubation Period:
Transmission: (2)
Age Preference: Percutaneous vs endemic areas
Pattern of Onset:

A

Incubation Period: ~60 days

Transmission:
Percutaneous
Close personal contact

Age Preference:
All ages (percutaneous)
Children and young adults (endemic areas)

Pattern of Onset: Acute

41
Q

HEV

Incubation Period:
Transmission:
Age Preference:
Pattern of Onset:

A

Incubation Period: ~40 days
Transmission: Fecal-oral
Age Preference: Adolescents and young adults
Pattern of Onset: Acute

42
Q

HAV

Fulminant Hepatitis?
Chronic Hepatitis?
Cirrhosis?
Predisposition to Hepatoma?

A

Possible but rare
No
No
No

43
Q

HBV

Fulminant Hepatitis?
Chronic Hepatitis?
Cirrhosis?
Predisposition to Hepatoma?

A

Possible but rare

5-10% of infected adults
90% of infected neonates

~25% of patients with chronic disease
Yes

44
Q

HCV

Fulminant Hepatitis?
Chronic Hepatitis?
Cirrhosis?
Predisposition to Hepatoma?

A

Possible but rare
Increased risk with HAV superinfection

85% of infected patients

~20% of patients with chronic disease

Yes

45
Q

HDV

Fulminant Hepatitis?
Chronic Hepatitis?
Cirrhosis?
Predisposition to Hepatoma?

A

Common

<5% in patients co-infected with HBV
80-95% in patients with pre-existing chronic HBV

15-30% of patients with chronic disease

Possible

46
Q

HEV

Fulminant Hepatitis?
Chronic Hepatitis?
Cirrhosis?
Predisposition to Hepatoma?

A

Common, especially in pregnant women

No

No

No

47
Q

HAV

Diagnosis
Acute Infection
Chronic Infection

A

Acute Infection: IgM anti-HAV

Chronic Infection: –

48
Q

HBV

Diagnosis
Acute Infection:
Chronic Infection:

A

Acute Infection: IgM anti-HBc (core Ag)

Chronic Infection:
HbsAg
IgG anti-HBc

49
Q

HCV

Diagnosis
Acute Infection:
Chronic Infection:

A

Acute Infection:
Serum HCV RNA

Chronic Infection:
Anti-HCV
Serum HCV RNA

50
Q

HDV

Diagnosis
Acute Infection:
Chronic Infection:

A

Acute Infection: Acute and convalescent anti-HDV

Chronic Infection: Anti-HDV (high titer)

51
Q

HEV

Diagnosis
Acute Infection:
Chronic Infection:

A

Acute Infection:

Chronic Infection: Anti-HEV

52
Q

HAV

PREVENTION AND TREATMENT
Passive Immunization:
Protective:
Effective Therapies:
(need to consider liver transplant for fulminant hepatitis and endstage chronic disease)
A

Immune globulin
Vaccine
No

53
Q

HBV

PREVENTION AND TREATMENT
Passive Immunization:
Protective:
Effective Therapies:
(need to consider liver transplant for fulminant hepatitis and endstage chronic disease)
A

HBV immune globulin

Vaccine

IFN-alpha
Lamivudine
Other anti-virals

54
Q

HCV

PREVENTION AND TREATMENT
Passive Immunization:
Protective:
Effective Therapies:
(need to consider liver transplant for fulminant hepatitis and endstage chronic disease)
A

No

No vaccine

IFN-alpha + ribavirin
Other anti-virals

55
Q

HDV

PREVENTION AND TREATMENT
Passive Immunization:
Protective:
Effective Therapies:
(need to consider liver transplant for fulminant hepatitis and endstage chronic disease)
A

No

HBV vaccine (indirect protection)

IFN-alpha (possibly)

56
Q

HEV

PREVENTION AND TREATMENT
Passive Immunization:
Protective:
Effective Therapies:
(need to consider liver transplant for fulminant hepatitis and endstage chronic disease)
A

No

Vaccine in production

No

57
Q

Acute HAV diagnosis:

Check for what? Why?

A

IgM Anti-HAV: check for IgM because that is indicative of a new infection; IgG is present for life

58
Q

Acute HBV diagnosis:
Why check for the Ab to the core Ag?
What causes a false negative?

A

IgM Anti-HBc: check for Ab to the core Ag because of the possible window period

Time during acute illness where HbsAg starts to go away (Abs being formed) but that HbsAb is not yet detectable; results in a false negative

59
Q

Acute HBV

What indicates recovery from infection?
When does HBsAg disappear?

A

Development of Anti-HBs antibodies: indicates recovery from infection (protective Ab); after this Ab develops, HBsAg disappears

60
Q

Chronic HBV

Anti-HBs:
What happens to HBsAg?

A

Anti-HBs does not develop: therefore, HBsAg stays elevated for years after exposure to HBV (HBeAg also present along with DNA polymerase)

61
Q

Chronic Hepatitis C

Anti-HCV ab:
What happens due to the development of ab?

A

Anti-HCV antibody is NOT protective: even though this Ab develops, chronic disease occurs anyways

Micro Exam 2 (18 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions